Erste Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Erste Asset Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-58,000	Closed	-$3.95M	–	604
2022 Q3	$3.95M	Hold	58,000	–	–	0.09%	225
2022 Q2	$1.87M	Hold	58,000	–	–	0.04%	287
2022 Q1	$2.03M	Buy	58,000 +4,500	+8%	+$135K	0.04%	293
2021 Q4	$1.62M	Hold	53,500	–	–	0.03%	315
2021 Q3	$1.38M	Hold	53,500	–	–	0.03%	309
2021 Q2	$1.74M	Hold	53,500	–	–	0.03%	297
2021 Q1	$2.18M	Hold	53,500	–	–	0.05%	259
2020 Q4	$2.36M	Hold	53,500	–	–	0.07%	244
2020 Q3	$2.89M	Hold	53,500	–	–	0.1%	204
2020 Q2	$3.56M	Hold	53,500	–	–	0.14%	162
2020 Q1	$2.78M	Sell	53,500 -10,300	-16%	-$690K	0.16%	153
2019 Q4	$5.05M	Hold	63,800	–	–	0.22%	110
2019 Q3	$3.14M	Hold	63,800	–	–	0.17%	138
2019 Q2	$3.44M	Buy	63,800 +34,800	+120%	+$2M	0.18%	129
2019 Q1	$1.51M	Buy	29,000 +13,000	+81%	+$639K	0.08%	204
2018 Q4	$638K	Buy	+16,000	New	+$600K	0.04%	274

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Erste Asset Management's GBT Position: Q4 2022 in Review

Erste Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 58,000 shares — an estimated $3.95M sold.

Erste Asset Management first reported a position in GBT in Q4 2018 and held it in 16 quarters. The position peaked at $5.05M in Q4 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Erste Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Erste Asset Management sold 58,000 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $3.95M.
Erste Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2018 and held it in 16 quarters.
Erste Asset Management's Global Blood Therapeutics, Inc. position peaked at $5.05M in Q4 2019.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Erste Asset Management's 13F filing for Q4 2022, filed 26 Nov 2024.